Press Releases Archivi

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval [...]

Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

BASEL, Switzerland – 11th December 2020: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed [...]

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

Article entitled ‘A genetic vaccine encoding shared cancer neoantigens to treat tumors with Microsatellite Instability’ published in Cancer Research BASEL, Switzerland – 22. July 2020: Nouscom, [...]

Nouscom Strengthens its Management Team

Marina Udier, PhD, appointed as Chief Executive Officer and Patricia Delaite, MD, appointed as Chief Medical Officer BASEL, Switzerland – 26. February 2020: Nouscom, an immuno-oncology company [...]

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

BASEL, Switzerland – 9 December 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been [...]

Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors

Article published in Nature Communications BASEL, Switzerland – 19 June 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced [...]

IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

BASEL, Switzerland – 3rd June 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug [...]

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

Nouscom Strengthens its Management Team

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors

IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

Okairos awarded by Swiss Biotech Association